Chronic inflammatory bowel diseases - New therapeutic approaches;Chronisch-entzündliche darmerkrankungen - Neue therapieansätze

Medizinische Klinik

Volumn 103, Issue 2, 2008, Pages 90-101

  Herrlinger, Klaus ^a   Stange, Eduard F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BASILIXIMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CERTOLIZUMAB PEGOL; DACLIZUMAB; ETANERCEPT; FONTOLIZUMAB; GAMMA INTERFERON ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATALIZUMAB; PLACEBO; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JEJUNUM; LOADING DRUG DOSE; STOMACH PAIN; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 39449107717     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-008-1013-3     Document Type: Article

References (59)

1. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-5.
2. Modigliani R, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
3. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-)colitis with azathioprine. Gastrointest Endosc 1999;50:667-71.
4. Lemann M, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-8.
5. Kozarek RA, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
6. D'Haens G, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
7. Hommes DBF, et al. A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): top-down vs. step-up strategies. Gastroenterology 2005;128:A577.
8. Cosnes J, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50.
9. Cosnes J, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41.
10. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755-8.
11. Baraliakos X, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-{alpha} antibody infliximab. Rheumatology (Oxf) 2007;46:1450-3.
12. Goekoop-Ruiterman YP, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
13. Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
14. Lemann M, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61.
15. Pearson DC, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000067.
16. Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
17. Present DH, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
18. Sands BE, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
19. Jarnerot G, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
20. Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
21. Colombel JF, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
22. Ljung T, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
23. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
24. Biancone L, et al. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4:78-91.
25. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
26. Stange EF, et al. [Diagnostics and treatment of Crohn's disease - results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases.] Z Gastroenterol 2003;41:19-20.
27. Travis SP, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55:Suppl 1:16-35.
28. Hanauer SB, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33, quiz 591.
29. Sandborn WJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
30. Colombel JF, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
31. Sandborn WJ, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007;146:829-38.
32. Schreiber S, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
33. Sandborn WJ, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
34. Schreiber S, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
35. Sandborn WJ, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004;53:1485-93.
36. Sandborn WJ, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
37. Vasiliauskas EA, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
38. Ghosh S, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
39. Sandborn WJ, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
40. Van Assche G, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
41. Schreiber S, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46.
42. Yacyshyn BR, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6.
43. Kasran A, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22:111-22.
44. Hommes D, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14.
45. Schreiber S, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34.
46. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473-82.
47. Sands BE, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999;117:58-64.
48. Sands BE, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002;16:399-406.
49. Herrlinger KR, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101:793-7.
50. Hommes DW, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-7.
51. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002;360:1478-80.
52. Korzenik JR, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-201.
53. Gordon FH, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74.
54. Van Assche G, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76.
55. Van Assche G, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-74.
56. Creed TJ, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75.
57. Creed TJ, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-42.
58. Vermeire S, van Assche V, Rutgeerts P. Review article: Altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3-12.
59. Wehkamp J, Schmid M, Stange EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 2007;23:370-8.